DCPH(Delisted)
DecipheraยทNASDAQ
--
--(--)
DCPH Profile
Deciphera Pharmaceuticals, Inc.
A biopharmaceutical company that developing new medicines for cancer
200 Smith Street, Waltham, MA, 02451
--
Deciphera Pharmaceuticals, Inc., is a biopharmaceutical company focused on discovering, developing and delivering important new drugs to patients to treat cancer. The company is leveraging its proprietary switch controlled kinase inhibitor platform and deep expertise in kinase biology to execute their strategy to develop a broad portfolio of innovative drugs. The company has an approved drug, Qin Rock, which is developed through their proprietary platform. In addition to Qin Luo, the company is developing three clinical-stage drug candidates and advancing its research-stage projects. The Company fully owns Qin Rock and all its drug candidates, with the exception of Qin Rock's development and commercialization license agreement in Greater China. The Company is preparing to launch QINLOCK in Europe, and the Company has entered into and intends to enter into selected reseller agreements in the future to offer QINLOCK in regions where the Company does not plan to distribute QINLOCK on its own (e.g. Australia and Canada).
